UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 512

Sortiert nach

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Investigational new drugs, 2016-12, Vol.34 (6), p.740-749

2016

Volltextzugriff (PDF)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

British journal of cancer, 2008-07, Vol.99 (1), p.51-56

2008

Volltextzugriff (PDF)

Tool wear modelling using micro tool diameter reduction for micro-end-milling of tool steel H13

International journal of advanced manufacturing technology, 2019-12, Vol.105 (5-6), p.2531-2542

2019

Volltextzugriff (PDF)

Residual stress in metal arc additive manufacturing of mill knives cutting edges

International journal of advanced manufacturing technology, 2019-10, Vol.104 (9-12), p.4457-4464

2019

Volltextzugriff (PDF)

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

British journal of cancer, 2014-08, Vol.111 (4), p.651-659

2014

Volltextzugriff (PDF)

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Annals of oncology, 2013-01, Vol.24 (1), p.145-152

2013

Volltextzugriff (PDF)

Effects of cutting parameters on roughness and residual stress of maraging steel specimens produced by additive manufacturing

International journal of advanced manufacturing technology, 2020-12, Vol.111 (9-10), p.2449-2459

2020

Volltextzugriff (PDF)

Value stream mapping and lean simulation: a case study in automotive company

International journal of advanced manufacturing technology, 2016-07, Vol.85 (1-4), p.547-555

2016

Volltextzugriff (PDF)

The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii547-viii547

2018

Volltextzugriff (PDF)

Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience

Annals of oncology, 2017-10, Vol.28, p.vi52-vi52

2017

Volltextzugriff (PDF)

Balanced Propofol Sedation in Patients Undergoing EUS-FNA: A Pilot Study to Assess Feasibility and Safety

Diagnostic and Therapeutic Endoscopy, 2011, Vol.2011, p.542159-5

2011

Volltextzugriff (PDF)

Investigation of load direction on the compressive strength of additively manufactured triply periodic minimal surface scaffolds

International journal of advanced manufacturing technology, 2020-07, Vol.109 (3-4), p.771-779

2020

Volltextzugriff (PDF)

Clinical experience with a new endoscopic over-the-scope clip system for use in the GI tract

Digestive and liver disease, 2009-06, Vol.41 (6), p.406-410

2009

Volltextzugriff (PDF)

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]

ESMO open, 2022-08, Vol.7 (4), p.100549-100549, Article 100549

2022

Volltextzugriff (PDF)

Investigation of micromilled tool steel H13 using tungsten carbide micro-end mills

International journal of advanced manufacturing technology, 2020-03, Vol.107 (3-4), p.1179-1189

2020

Volltextzugriff (PDF)

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

European journal of cancer (1990), 2014-11, Vol.50, p.171-171

2014

Volltextzugriff (PDF)

OC.01.6 EUS-FNA OF NON MASS-FORMING CHOLANGIOCARCINOMA WITH A 25 G PROCORE NEEDLE. A CASE SERIES

Digestive and liver disease, 2014-03, Vol.46, p.S6-S6

2014

Volltextzugriff (PDF)

1257 POSTER Phase I Safety and Tolerability Study of Olaparib (AZD2281) in Combination With Liposomal Doxorubicin (PLD) in Patients With Advanced Metastatic Solid Tumours

European journal of cancer (1990), 2011, Vol.47, p.S161-S162

2011

Volltextzugriff (PDF)

Simulation and analysis of error impact on freeform surface milling

International journal of advanced manufacturing technology, 2014, Vol.70 (1-4), p.607-620

2014

Volltextzugriff (PDF)

1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study

Annals of oncology, 2023-10, Vol.34, p.S965-S965

2023

Volltextzugriff (PDF)

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Journal of clinical oncology, 2006-03, Vol.24 (9), p.1443-1448

2006

Volltextzugriff (PDF)

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

Annals of oncology, 2022-05, Vol.33, p.S196-S196

2022

Volltextzugriff (PDF)

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

European journal of cancer (1990), 2020-10, Vol.138, p.S5-S6

2020

Volltextzugriff (PDF)

LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Annals of oncology, 2021-09, Vol.32, p.S1303-S1303

2021

Volltextzugriff (PDF)

1 – 25 von 512

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(382)
Mit Volltextzugriff
(333)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(236)
Science & Technology
(164)
Life Sciences & Biomedicine
(143)
Female
(132)
Male
(117)
Middle Aged
(100)
Adult
(90)
Aged
(84)
Biological And Medical Sciences
(63)
Oncology
(45)
Medical Sciences
(43)
Food Science & Technology
(32)
Adolescent
(21)
Fundamental And Applied Biological Sciences. Psychology
(21)
Italy
(21)
Old Medline
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(20)
Aged, 80 And Over
(19)
Chemotherapy
(19)
Pharmacology. Drug Treatments
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

Tool wear modelling using micro tool diameter reduction for micro-end-milling of tool steel H13

Residual stress in metal arc additive manufacturing of mill knives cutting edges

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Effects of cutting parameters on roughness and residual stress of maraging steel specimens produced by additive manufacturing

Value stream mapping and lean simulation: a case study in automotive company

The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors

Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience

Balanced Propofol Sedation in Patients Undergoing EUS-FNA: A Pilot Study to Assess Feasibility and Safety

Investigation of load direction on the compressive strength of additively manufactured triply periodic minimal surface scaffolds

Clinical experience with a new endoscopic over-the-scope clip system for use in the GI tract

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]

Investigation of micromilled tool steel H13 using tungsten carbide micro-end mills

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

OC.01.6 EUS-FNA OF NON MASS-FORMING CHOLANGIOCARCINOMA WITH A 25 G PROCORE NEEDLE. A CASE SERIES

1257 POSTER Phase I Safety and Tolerability Study of Olaparib (AZD2281) in Combination With Liposomal Doxorubicin (PLD) in Patients With Advanced Metastatic Solid Tumours

Simulation and analysis of error impact on freeform surface milling

1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Suchergebnisse filtern